63PEXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors. (5th March 2018) - Le Saux, O; Italiano, A; Spaeth, D; Heudel, P-E; Filleron, T; Pezzella, V; Jimenez, M; Legrand, F; Ferté, C